April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Intraocular Bevacizumab for Macular Edema Due to Crvo. A Multifocal-Erg and Oct Study
Author Affiliations & Notes
  • M. M. Moschos
    Ophthalmology, University of Athens, Athens, Greece
  • A. Triglianos
    Ophthalmology, University of Athens, Athens, Greece
  • P. Minogiannis
    Ophthalmology, University of Athens, Athens, Greece
  • I. Markopoulos
    Ophthalmology, University of Athens, Athens, Greece
  • M. Apostolopoulos
    Ophthalmology, University of Athens, Athens, Greece
  • M. Moschos
    Ophthalmology, University of Athens, Athens, Greece
  • Footnotes
    Commercial Relationships  M.M. Moschos, None; A. Triglianos, None; P. Minogiannis, None; I. Markopoulos, None; M. Apostolopoulos, None; M. Moschos, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 3287. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. M. Moschos, A. Triglianos, P. Minogiannis, I. Markopoulos, M. Apostolopoulos, M. Moschos; Intraocular Bevacizumab for Macular Edema Due to Crvo. A Multifocal-Erg and Oct Study. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3287.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate by mfERG and OCT the effectiveness of intravitreal use of bevacizumab (Avastin) in the treatment of macular edema due to central retinal vein occlusion (CRVO).

Results: : Before treatment, OCT shows an increase of the retinal thickness of the fovea. One and 3 months after treatment the foveal thickness decreased to a significant level. The electrical responses in the fovea and parafovea of the mfERG recording depicted a significant improvement at 1 and 3 months after the injection. No patient manifested intraocular pressure increase.

Conclusions: : The intravitreal use of bevacizumab may provide anatomical and functional amelioration of the macula in patients with macular edema due to CRVO. However, further study is needed in order to assess the treatment's long-term efficacy.

Keywords: electrophysiology: clinical • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×